At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LGVN Longeveron Inc
Market Closed 10-09 16:00:00 EDT
2.48
+0.11
+4.64%
盘后2.48
+0.000.00%
19:04 EDT
High2.60Low2.34Vol58.46K
Open2.40D1 Closing2.37Amplitude10.97%
Mkt Cap7.84MTradable Cap6.76MTotal Shares3.16M
T/O141.56KT/O Rate2.14%Tradable Shares2.73M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Longeveron Says Phase 2b Trial Shows Laromestrocel Improves Physical Condition in Age-Related Frailty Patients
Reuters  ·  10-01
Longeveron Says Phase 2b Trial Shows Laromestrocel Improves Physical Condition in Age-Related Frailty Patients
Longeveron to Participate in Three Longevity/Aging Investment Conferences
GlobeNewswire  ·  10-01
Longeveron to Participate in Three Longevity/Aging Investment Conferences
Longeveron Says ELPIS II Phase 2b Trial of Laromestrocel in HLHS Misses Primary Endpoint at 12 Months
Reuters  ·  09-24
Longeveron Says ELPIS II Phase 2b Trial of Laromestrocel in HLHS Misses Primary Endpoint at 12 Months
Analysts Offer Insights on Healthcare Companies: Bausch + Lomb Corporation (BLCO) and Longeveron (LGVN)
TIPRANKS  ·  09-21
Analysts Offer Insights on Healthcare Companies: Bausch + Lomb Corporation (BLCO) and Longeveron (LGVN)
Top Midday Decliners
MT Newswires Live  ·  09-18
Top Midday Decliners
Longeveron Stock (LGVN) Plummets 56% on a Failed Clinical Trial
TIPRANKS  ·  09-18
Longeveron Stock (LGVN) Plummets 56% on a Failed Clinical Trial
Stocks to Watch: Generac, Vicor, Longeveron, Viant
Dow Jones  ·  09-17
Stocks to Watch: Generac, Vicor, Longeveron, Viant
Longeveron Explores Strategic Options After Therapy Fails Mid-Stage Trial for Infant Heart Condition
Reuters  ·  09-17
Longeveron Explores Strategic Options After Therapy Fails Mid-Stage Trial for Infant Heart Condition
Longeveron Exploring Options to Maximize Shareholder Value After Heart Disease Drug Misses Endpoint
Dow Jones  ·  09-17
Longeveron Exploring Options to Maximize Shareholder Value After Heart Disease Drug Misses Endpoint
Longeveron Says ELPIS II Trial of Laromestrocel in Hypoplastic Left Heart Syndrome Misses Primary Endpoint
Reuters  ·  09-17
Longeveron Says ELPIS II Trial of Laromestrocel in Hypoplastic Left Heart Syndrome Misses Primary Endpoint
Longeveron to resume trading at 5:55 pm ET
TIPRANKS  ·  09-17
Longeveron to resume trading at 5:55 pm ET
Longeveron’s laromestrocel did not meet primary endpoint in Phase 2b HLHS trial
TIPRANKS  ·  09-17
Longeveron’s laromestrocel did not meet primary endpoint in Phase 2b HLHS trial
Longeveron exploring all options for maximizing shareholder value
TIPRANKS  ·  09-17
Longeveron exploring all options for maximizing shareholder value
Longeveron Announces Topline Results from Elpis Ii Phase 2B Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (Hlhs)
THOMSON REUTERS  ·  09-17
Longeveron Announces Topline Results from Elpis Ii Phase 2B Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (Hlhs)
Longeveron - no Deaths in Laromestrocel-Treated Patients over 12 Months
THOMSON REUTERS  ·  09-17
Longeveron - no Deaths in Laromestrocel-Treated Patients over 12 Months
Longeveron - Company Initiates Process to Optimize Cost Containment and Maximize Shareholder Value
THOMSON REUTERS  ·  09-17
Longeveron - Company Initiates Process to Optimize Cost Containment and Maximize Shareholder Value
Longeveron: Intends to Pursue Funding Sources & Other Potential Revenue Opportunities to Advance Laromestrocel in Longevity & Aging-Related Frailty
THOMSON REUTERS  ·  09-17
Longeveron: Intends to Pursue Funding Sources & Other Potential Revenue Opportunities to Advance Laromestrocel in Longevity & Aging-Related Frailty
Longeveron Inc: Initiated a Process to Review All Options
THOMSON REUTERS  ·  09-17
Longeveron Inc: Initiated a Process to Review All Options
Longeveron - Elpis Ii Trial Did not Meet Primary Endpoint of Rvef Improvement at Month 12
THOMSON REUTERS  ·  09-17
Longeveron - Elpis Ii Trial Did not Meet Primary Endpoint of Rvef Improvement at Month 12
Longeveron Inc trading halted, news pending
TIPRANKS  ·  09-17
Longeveron Inc trading halted, news pending

Introduction

Company Name.
Longeveron Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, a candidate in Phase 2a/b trials that is used for the treatment of alzheimer's disease, hypoplastic left heart syndrome, and aging-related frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Issue price:
--